T-group (topology)
325.1.4 Nicotinate/Quinolinate PRTase N-terminal domain-like
Ligands and drugs
722
Member domains
285
with ligand contacts (≤ 4 Å)
39.5% of members
253
with DrugDomain annotations
35.0% of members
212
with a DrugBank compound
29.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 325.1.4 belongs to X-group 325 alpha/beta-Hammerhead/Barrel-sandwich hybrid, which binds 8.9 ligand superclasses per 20 proteins, broader than 75% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB01796 | NTM | Quinolinic Acid | 18 |
| DB02746 | PHT | Phthalic Acid | 14 |
| DB03227 | NMN | Nicotinamide Mononucleotide | 14 |
| DB14756 | SRT | meso-Tartaric acid | 12 |
| DB02701 | NCA | Nicotinamide | 10 |
| DB12731 | DGB | Daporinad | 8 |
| DB01632 | PRP | 5-O-phosphono-alpha-D-ribofuranosyl diphosphate | 6 |
| DB03942 | PCP | Carboxylic PRPP | 6 |
| DB04294 | PPC | 5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate | 6 |
| DB03148 | A12 | Adenosine 5'-methylenediphosphate | 4 |
| DB02382 | NCN | Namn | 3 |
| DB00627 | NIO | Niacin | 2 |
| DB04160 | PPV | Pyrophosphoric acid | 2 |
| DB12980 | 2QG | CHS-828 | 2 |
| DB16761 | 2HJ | STF-31 | 2 |
| DB19243 | 96Q | Padnarsertib | 2 |
| DB02175 | MLA | Malonic acid | 1 |
| DB03570 | 144 | Tris-Hydroxymethyl-Methyl-Ammonium | 1 |
| DB04447 | DTT | 1,4-Dithiothreitol | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 27 |
| NCA | NICOTINAMIDE | 21 |
| NMN | BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE | 17 |
| NTM | QUINOLINIC ACID | 16 |
| PHT | PHTHALIC ACID | 14 |
| SRT | S,R MESO-TARTARIC ACID | 12 |
| MGmetal | MAGNESIUM ION | 10 |
| DGB | (2E)-N-{4-[1-(benzenecarbonyl)piperidin-4-yl]butyl}-3-(pyridin-3-yl)prop-2-enamide | 8 |
| PRP | 1-O-pyrophosphono-5-O-phosphono-alpha-D-ribofuranose | 8 |
| PCP | 1-ALPHA-PYROPHOSPHORYL-2-ALPHA,3-ALPHA-DIHYDROXY-4-BETA-CYCLOPENTANE-METHANOL-5-PHOSPHATE | 6 |
| POP | PYROPHOSPHATE 2- | 6 |
| PPC | 1-O-[(R)-hydroxy(phosphonomethyl)phosphoryl]-5-O-phosphono-alpha-D-ribofuranose | 6 |
| 1QS | N-{4-[(3,5-difluorophenyl)sulfonyl]benzyl}imidazo[1,2-a]pyridine-6-carboxamide | 4 |
| 2P1 | N-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}benzyl)-2H-pyrazolo[3,4-b]pyridine-5-carboxamide | 4 |
| 7YX | N-[4-[(4R)-1-cyclopentyl-4-methyl-6-oxidanylidene-4,5-dihydropyridazin-3-yl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide | 4 |
| 7Z2 | N-[4-[(5R)-1-(4-azanylbutyl)-6-oxidanylidene-5-quinolin-5-yl-4,5-dihydropyridazin-3-yl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide | 4 |
| A12 | PHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER | 4 |
| AMP | ADENOSINE MONOPHOSPHATE | 4 |
| BWA | N-{4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-N'-[(pyridin-3-yl)methyl]urea | 4 |
| CVJ | (1S,2S)-N-{4-[(1S)-1-(propanoylamino)ethyl]phenyl}-2-(pyridin-3-yl)cyclopropane-1-carboxamide | 4 |